

Research Article

Enzymes Inhibition and Antidiabetic Effect of Isolated Constituents from *Dillenia indica*

Sunil Kumar,¹ Vipin Kumar,² and Om Prakash¹

¹ Institute of Pharmaceutical Sciences, Kurukshetra University, Kurukshetra, Haryana 136119, India

² Department of Pharmacy, School of Chemical Sciences and Pharmacy, Central University of Rajasthan, Ajmer 305801, India

Correspondence should be addressed to Sunil Kumar; sunilmadhuban@yahoo.com

Received 11 April 2013; Revised 24 September 2013; Accepted 25 September 2013

Academic Editor: Ronald E. Baynes

Copyright © 2013 Sunil Kumar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Aims. This study was designed to investigate the enzyme inhibitory and antidiabetic activity for the constituents isolated from *Dillenia indica*. **Methods.** The leaves of *D. indica* were extracted with methanol and subjected to fractionation and chromatographic separation, which led to the isolation of seven compounds: betulinic acid (1), n-heptacosan-7-one (2), n-nonatriacontan-18-one (3), quercetin (4), β sitosterol (5), stigmasterol (6), and stigmasteryl palmitate (7). Among these isolates, compounds 1, 4, 5, and 6 were evaluated for *in vitro* enzyme inhibition and compounds 4, 5 and 6 were evaluated for antidiabetic activity in streptozotocin-nicotinamide induced diabetic mice. **Results.** Compounds 1, 4, 5, and 6 showed 47.4, 55.2, 48.8, and 44.3% α -amylase inhibition, respectively, and 52.2, 78.2, 52.5, and 34.2% α -glucosidase inhibition, respectively, at the dose of 50 μ g/kg. Compounds 4, 5 and 6 also showed significant (* $P < 0.05$) antidiabetic activity in streptozotocin-nicotinamide induced diabetic mice at the dose of 10 mg/kg. **Conclusion.** These results provide evidence that *Dillenia indica* might be a potential source of antidiabetic agents.

1. Introduction

Diabetes mellitus is a metabolic disorder resulting from a defect in insulin secretion, insulin action, or both. Worldwide, the total number of people with diabetes is projected to increase from 171 million in 2000 to 366 million in 2030 [1]. One therapeutic approach to decrease the hyperglycemia, especially after a meal, is to retard and reduce the digestion and absorption of ingested carbohydrates through the inhibition of carbohydrate hydrolyzing enzymes (α -amylase and α -glucosidase) in the digestive organs. As a result, these inhibitors could decrease the postprandial rise in blood glucose concentration [2]. α -Amylase is one of the enzymes in the digestive system that catalyses the breakdown of starch to maltose and finally to glucose, which is the only sugar that can be utilized by the body [3]. Therefore, natural inhibitors from the dietary plants show lower inhibitory effect against α -amylase activity and can be used as effective therapy for postprandial hyperglycemia with minimal side effects [4]. α -Glucosidase inhibitors can retard the liberation of glucose from dietary complex carbohydrates and delay glucose absorption, resulting in reduced postprandial plasma

glucose levels and suppressed postprandial hyperglycemia [5]. So, α -amylase and α -glucosidase inhibitors are drug-design targets in the development of compounds for the treatment of diabetes, obesity, and hyperlipaemia [6]. Many plant extracts and phytoconstituents showed *in vitro* α -glucosidase inhibition effect [7]. Furthermore, herbal treatment is preferred for diabetes due to lesser side effects and low cost [8].

Dillenia indica (Family: Dilleniaceae) is commonly called "Elephant tree." The bark and leaves have astringent effects. The fruit shows laxative properties and is used for relieving abdominal pain [9]. The juices of *D. indica* leaves, bark, and fruits are mixed and given orally for the treatment of cancer and diarrhea [10]. Fruits and leaves extracts of *D. indica* are reported to have antioxidant activity [11], CNS depressant activities [12], and anti-inflammatory activity [13] in mice. The alcoholic extract of the leaves of *D. indica* has antimicrobial activity [14]. Traditionally, the plant is also used for treatment of diabetes [15]. The methanolic extract also shows free radicals scavenging effect [16]. The methanolic leaves extract of plant shows antidiabetic activity in alloxan and streptozotocin induced diabetes [17, 18].

As in our previous work, ethyl acetate fraction of methanolic leaves extract of plant also shows antidiabetic activity in streptozotocin and streptozotocin-nicotinamide induced diabetes [19]. So, phytoconstituents were isolated from the active fraction and their antidiabetic activity was checked *in vivo* as well as their enzyme inhibition effect against α -amylase and α -glucosidase.

2. Material and Methods

2.1. Plant Material. *Dillenia indica* leaves were collected from the campus of Kurukshetra University, Kurukshetra, India, and were identified by Dr. H. B. Singh, Scientist F & Head, Raw Material Herbarium & Museum, NISCAIR, New Delhi, India. A voucher specimen of the plant is preserved in the herbarium (NISCAIR/RHMD/Consult/-2009-10/1381/182/1).

2.2. Extract Preparation and Fractionation. The collected leaves were washed with distilled water and dried in shade. The dried leaves were powdered by using dry grinder and passed through sieve. The powdered material (4.7 kg) was extracted with methanol by Soxhlet's apparatus. The extract was evaporated to dryness under reduced pressure at 45°C to give solid residues. The solid extract was suspended in water and successively extracted with hexane, ethyl acetate, and n-butanol by separating funnel (Figure 1). Each fraction was stored in airtight containers in refrigerator below 10°C for subsequent experiments.

2.3. Isolation of Phytoconstituents. The ethyl acetate fraction (50 g) was subjected to silica gel (number 60–120) column chromatography (CC) and eluted with pure hexane. Then it was further eluted successively, in order to increase polarity of the solvents in various combinations like hexane: chloroform; chloroform; chloroform: methanol. On the basis of TLC pattern, fractions DIC²³ to DIC²⁹ eluted with mobile phase (CHCl₃:CH₃OH; 90:10) were mixed together, dried, and recrystallized to obtain 73 mg of whitish/colourless crystals of compound 1. Compound 2 (71 mg of colourless amorphous powder) was obtained from fractions DIC³⁸ to DIC⁴⁴ after elution with mobile phase (CHCl₃:CH₃OH; 75:25). Fractions (DIC⁵⁰ to DIC⁵⁹) eluted from the column with solvent system (CHCl₃:CH₃OH; 60:40 & 50:50) gave 65 mg of pale yellow amorphous powder of compound 3. Compound 4 (53 mg of pale yellow amorphous powder) was obtained from fractions DIC⁷³ to DIC⁸⁰ after elution with mobile phase (CHCl₃:CH₃OH; 20:80).

Fractions DIC⁴ to DIC⁸ were collected with mobile phase hexane: chloroform; 50:50 and fractions DIC⁹ to DIC¹¹ were collected with mobile phase pure chloroform and were pooled on the basis of TLC. These were concentrated and dried in vacuum oven to obtain 210 mg of crude mass (DID) for rechromatography. Fractions (DID¹¹ to DID²⁰) eluted from the column with solvent system (chloroform: methanol; 98:2) gave 35 mg of whitish/colourless crystalline compound 5. Fractions (DID²⁵ to DID³¹) eluted from the column with solvent system (chloroform: methanol; 90:10) gave 41 mg of whitish/colourless crystalline compound 6. 32 mg of

colourless crystalline compound 7 was obtained from fractions (DID⁴⁰ to DID⁵¹) after elution from the column with solvent system (chloroform: methanol; 75:25 and 70:30).

2.4. Spectra of Isolated Phytoconstituents

2.4.1. Betulinic Acid (1). IR γ_{\max} (KBr): 3448, 2939, 2870, 2361, 1736, 1682, 1458, 1373, 1234, 1188, 1041, 887 cm⁻¹.

¹H NMR (CDCl₃): δ 4.46 (1H, brs, C-29a) 4.48 (1H, brs, C-29b), 3.20 (1H, dd, J = 5.1 Hz, H-3 α), 2.97 (1H, m, H-19), 1.60 (3H, s, Me-30), 1.28 (3H, brs, Me-23), 0.98 (3H, brs, Me-25), 0.95 (3H, brs, Me-26), 0.94 (3H, brs, Me-27), 0.73 (3H, brs, Me-24).

+ve ESI MS m/z : 457 [M+1]⁺ (C₃₀H₄₉O₃), 439 (M-H₂O)⁺, 411 (M-COOH)⁺.

2.4.2. n-Heptacosan-7-one (2). IR γ_{\max} (KBr): 2916, 2847, 1705, 1466, 1373, 1324, 1112, 1049, 725 cm⁻¹.

¹H NMR (CDCl₃): δ 2.34 (2 H, t, J = 7.5 Hz, H₂-6), 2.01 (2H, t, J = 7.2 Hz, H₂-8), 1.65 (10 H, brs, 5 \times CH₂), 1.55 (2H, m, CH₂), 1.26 (32 H, brs, 16 \times CH₂), 0.87 (3 H, t, J = 6.5 Hz, CH₃-1), 0.81 (3 H, t, J = 6.3 Hz, CH₃-27).

+ve ESI MS m/z : 395 [M+1]⁺ (C₂₇H₅₅O⁻).

2.4.3. n-Nonatriacontan-18-one (3). IR γ_{\max} (KBr): 2924, 2854, 1706, 1458, 1288, 1250, 941, 725 cm⁻¹.

¹H NMR (CDCl₃): δ 2.34 (2 H, t, J = 7.5 Hz, H₂-17), 2.05 (2 H, t, J = 6.6 Hz, H₂-19), 1.66 (4H, m, 2 \times CH₂), 1.32 (30 H, brs, 15 \times CH₂), 1.27 (34 H, brs, 17 \times CH₂), 0.89 (3H, t, J = 6.1 Hz, Me-1), 0.84 (3H, Me-39).

+ve ESI MS m/z : 563 [M+1]⁺, (C₃₉H₇₉O), 295.

2.4.4. Quercetin (4). IR γ_{\max} (KBr): 3394, 3310, 1659, 1605, 1558, 1520, 1450, 1381, 1311, 1257, 1196, 1095, 818, 795 cm⁻¹.

¹H NMR (DMSO): δ 7.81 (1H, brs, H-6'), 7.67 (1H, d, J = 2.0 Hz, H-2'), 6.9 (1H, d, J = 8.2 Hz, H-5'), 6.47 (1H, brs, H-8), 6.18 (1H, brs, H-6).

+ve ESI MS m/z : 303 [M+1]⁺, 302.

2.4.5. β -Sitosterol (5). IR γ_{\max} (KBr): 3441, 2942, 2362, 2340, 1694, 1542, 1460, 1385, 1032, 997, 785, 668 cm⁻¹.

¹H NMR (CDCl₃): δ 5.34 (1H, d, J = 5.02 Hz, CH), δ 3.52 (1H, m), 1.00 (3H, s, CH₃) δ 0.91 (3H, d, J = 6.4 Hz, CH₃), 0.83 (3H, d, J = 6.4 Hz, CH₃), 0.87 (3H, d, J = 6.4 Hz, Me), 0.89 (3H, d, J = 6.4 Hz), 0.81 (3H, d, J = 6.4 Hz, Me), δ 0.74 (3H, s, CH₃).

+ve ESI MS m/z : 415 [M+1]⁺, 414 [M]⁺, 396, 255.

2.4.6. Stigmasterol (6). IR γ_{\max} (KBr): 3412, 1665 cm⁻¹.

¹H NMR (CDCl₃): δ 5.36 (1H, m, CH), δ 5.15 (2H, m, CH=CH), δ 3.52 (1H, m, CH), 1.00 (3H, s, CH₃) δ 0.93 (3H, d, J = 6 Hz CH₃), 0.83 (3H, d, J = 5.4 Hz, CH₃), 0.81 (3H, s, CH₃), 0.79 (3H, d, J = 6.4 Hz, CH₃), δ 0.67 (3H, s, Me).

+ve ESI MS m/z : 413 [M+1]⁺, 412 [M]⁺ (C₂₉H₄₈O), 394, 351, 271, 213, 173, 159, 145, 105, 91, 81, 55.

2.4.7. Stigmasteryl Palmitate (7). IR γ_{\max} (KBr): 2924, 2854, 2361, 1721, 1651, 1458, 1373, 1250, 1112, 1041, 964, 802, 725 cm⁻¹.




FIGURE 1: Schematic representation of extraction and fractionation of *D. indica*.

$^1\text{H NMR}$ (CDCl_3): δ 5.36 (1H, m, H-6) 5.20 (1H, m, H-22), 5.05 (1H, m, H-23), 3.54 (1H, brs, H-3 α), 2.33 (2H, m, H₂-21), 1.27 (26H, brs, 13 \times CH₂), 1.02 (3H, brs, Me-19), 0.95 (3H, d, $J = 6.5$ Hz, Me-21), 0.89 (3H, d, $J = 6.5$ Hz, Me-26), 0.87 (3H, d, $J = 6.2$ Hz, Me-27), 0.84 (3H, t, $J = 6.6$ Hz, Me-16), 0.82 (3H, d, $J = 6.1$ Hz, Me-29), 0.69 (3H, brs, Me-18).

+ve ESI MS m/z : 651 $[\text{M}+1]^+$, 650 $[\text{M}]^+$ ($\text{C}_{45}\text{H}_{78}\text{O}_2$), 411, 397, 395, 381, 255.

2.5. α -Amylase Inhibition. Starch azure (2 mg) was suspended in a tube containing 0.2 mL of 0.5 M Tris-HCl buffer (pH 6.9) containing 0.01 M calcium chloride (substrate). The tubes were boiled for 5 min and then preincubated at 37°C for 5 min. 1 mL of 0.1% of dimethyl sulfoxide was used to dissolve 1 mg of isolated fractions in order to obtain concentrations of 20, 40, 60, 80, and 100 $\mu\text{g}/\text{mL}$. Then 0.2 mL of isolated fraction of a particular concentration was added in the tube containing the substrate solution. 0.1 mL of porcine pancreatic amylase in Tris-HCl buffer (2 units/mL) was added to the tube containing the isolated fraction and substrate solution and all

the processes were carried out at 37°C for 10 min. The reaction was stopped by adding 0.5 mL of 50% acetic acid in each tube. The reaction mixture was then centrifuged at 3000 rpm for 5 min and the absorbance of the resulting supernatant was measured at 595 nm spectrometrically [20]:

The α -amylase inhibitory activity

$$= \frac{(\text{Ac}^+) - (\text{Ac}^-) - (\text{As} - \text{Ab})}{(\text{Ac}^+) - (\text{Ac}^-)} \times 100, \quad (1)$$

where Ac^+ is absorbance of 100% enzyme activity (only solvent with enzyme), Ac^- is absorbance of 0% enzyme activity (only solvent without enzyme), As is absorbance of test sample (with enzyme), and Ab is absorbance of blank (a test sample without enzyme), respectively.

2.6. α -Glucosidase Inhibition. α -Glucosidase (50 μL , 0.5 U/mL) and 0.2 M potassium phosphate buffer (pH 6.8, 50 μL) were mixed with test sample (at various concentrations).




FIGURE 2: Chemical structures of isolated phytoconstituents.

After incubation at 37°C for 15 min, 3 mM pNPG (100 μL) was added. The reaction was incubated again at 37° for 10 min and then stopped by 0.1 M Na_2CO_3 . The absorption of 4-nitrophenol was measured at 405 nm [21]. The reaction mixture without sample was used as a control, and the mixture without substrate was used as a blank.

The percentage inhibition of α -glucosidase was calculated as follows:

$$\text{Inhibition rate (\%)} = \{1 - ((\text{Abs sample} - \text{Abs blank}) / (\text{Abs control}))\} \times 100,$$

where Abs sample is the absorbance of the experimental sample, Abs blank is the absorbance of the blank, and Abs control is the absorbance of the control.

2.7. Antidiabetic Activity. Noninsulin dependent diabetes (NIDDM) was induced in overnight fasted mice by a single intraperitoneal injection of 100 mg/kg STZ, 15 min after the i.p. administration of 240 mg/kg nicotinamide. Hyperglycemia was confirmed by the elevated blood glucose levels determined at 72 h and then on day 7 of the injection. Only mice confirmed with permanent NIDDM were used in the antidiabetic study [22]. For screening antidiabetic effect of isolated phytoconstituents, the overnight fasted mice were divided into six groups with five animals each and treated orally once as follows:

group I: normal healthy control: received only vehicle (Tween 80, 2% v/v);

group II: diabetic control: received only vehicle (Tween 80, 2% v/v);

group III: diabetic mice received quercetin (10 mg/kg body wt.);

group IV: diabetic mice received β -sitosterol (10 mg/kg body wt.);

group V: diabetic mice received stigmasterol (10 mg/kg body wt.);

group VI: diabetic mice received glibenclamide (10 mg/kg).

Experiments were performed in mice that had been fasted overnight (deprived of food for at least 12 h but allowed free access to water). Single dose of drug solutions or vehicle was administered orally by gastric intubation. The effect of vehicle, compounds, and standard drug on blood glucose level was determined in the animals at 0, 4, 8, and 24 h after daily oral administration. Blood samples were taken from the tip of the tail of the mice of different groups under mild ether anesthesia and glucose levels were determined by using blood glucose test strips with elegance glucometer (Frankenberg, Germany).

2.8. Statistical Analysis. All the results are presented as mean \pm standard error of mean (SEM). The statistical analysis involving two groups was evaluated by means of Student's *t*-test, whereas one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparison posttest was used

TABLE 1: Phytoconstituents isolated by column chromatography.

Sr. number	Compounds	m. p. (°C)	TLC solvent system	R_f value
1	Betulinic acid	297–300	Chloroform : methanol : formic acid (98 : 2 : 2)	0.35
2	n-Heptacosan-7-one	88–90	CHCl ₃ : MeOH (95 : 5)	0.53
3	n-Nonatriacontan-18-one	89–92	CHCl ₃ : MeOH (95 : 5)	0.42
4	Quercetin	310–313	CHCl ₃ : MeOH (95 : 5)	0.44
5	β -Sitosterol	137–139	CHCl ₃ : MeOH (90 : 10)	0.55
6	Stigmasterol	164–167	CHCl ₃ : CH ₃ OH (90 : 10)	0.45
7	Stigmasteryl palmitate	94–97	Chloroform : methanol (95 : 5)	0.64

m.p.: melting point, R_f : retention factor.

TABLE 2: Enzyme inhibition activity of isolated constituents.

Constituents	Conc.	α -Amylase (% inhibition)	α -Glucosidase (% inhibition)
Betulinic acid	50 μ g/mL	47.4 \pm 4.3*	52.2 \pm 3.8*
Quercetin	50 μ g/mL	55.2 \pm 4.4*	78.2 \pm 2.6*
β -Sitosterol	50 μ g/mL	48.8 \pm 2.3*	52.5 \pm 2.4*
Stigmasterol	50 μ g/mL	44.3 \pm 2.4*	34.2 \pm 3.7

Data represent means \pm SEM, * $P < 0.05$.

for statistical comparison between control and various treated groups. Statistical significance was accepted at the $P < 0.05$ values.

3. Results and Discussion

The chemical structures of isolated constituents were established after interpretation of spectral data. Their melting points were measured and thin layer chromatography study was done as shown in Table 1. From aggregating all data, the chemical structures of seven compounds, betulinic acid, n-heptacosan-7-one, n-nonatriacontan-18-one, quercetin, β -sitosterol, stigmasterol, and stigmasteryl palmitate, were established as shown in Figure 2.

In the present study, *in vitro* α -amylase and α -glucosidase inhibition effect of betulinic acid, quercetin, β -sitosterol, and stigmasterol was studied at 50 μ g/mL concentration. The phytoconstituents showed good *in vitro* enzyme inhibition activity. Betulinic acid, quercetin, β -sitosterol, and stigmasterol showed 47.4 \pm 4.3, 55.2 \pm 4.4, 48.8 \pm 2.3, and 44.3 \pm 2.4% α -amylase inhibition, respectively, and 52.2 \pm 3.8, 78.2 \pm 2.6, 52.5 \pm 2.4, and 34.2 \pm 3.79% α -glucosidase inhibition, respectively, at the dose of 50 μ g/kg (Table 2). Triterpenoids, flavonoids, and steroids isolated from various plants have also shown α -glucosidase inhibition activity [7]. α -Glucosidase is an exo-type carbohydrase distributed widely in microorganisms, plants, and animal tissues [23], which catalyzes the liberation of α -glucose from the nonreducing end of the substrate. Inhibiting this enzyme slows the elevation of blood sugar following a carbohydrate meal [5]. It is a membrane bound enzyme present in the epithelium of the small intestine, which works to facilitate the absorption of glucose by the small intestine by catalyzing the hydrolytic cleavage of oligosaccharides into absorbable monosaccharides. By inhibition of α -glucosidase in the intestine, the rate of hydrolytic cleavage of oligosaccharide is decreased and the

process of carbohydrate digestion spreads to the lower part of small intestine [7]. This spreading of digestion process delays the overall absorption rate of glucose into the blood.

Streptozotocin possesses diabetogenic properties mediated by pancreatic beta cell destruction and this compound has been widely used to induce diabetes in experimental animals [24]. The isolated phytoconstituents quercetin, β -sitosterol, and stigmasterol from *D. indica* were also evaluated for type-2 diabetic in mice. The effect of compounds and glibenclamide on blood glucose level was determined in the animals at 0, 4, 8, 24 h after daily oral administration at the dose of 10 mg/kg. Quercetin, β -sitosterol, and stigmasterol showed significant reduction in blood glucose level as compared to the control group (Table 3).

In our previous works, methanolic leaves extract *D. indica* had shown antidiabetic and antihyperlipidemic effect in alloxan and streptozotocin induced diabetic rats [17, 18]. Histopathological analysis showed that the extract has protective effect on vital organs (liver, kidney, and pancreas) in alloxan induced diabetic rats [17]. Further, fractionation of methanolic leaves extract was done as shown in Figure 2 and ethyl acetate fraction was evaluated for antidiabetic and hypolipidemic activities. The ethyl acetate fraction showed significant antidiabetic and hypolipidemic effect at a dose of 400 mg/kg in both type 1 and type 2 diabetic rats [19]. For confirmation of phytoconstituents responsible for activity of the plant, the ethyl acetate fraction of methanolic leaves extract was subjected to column chromatography and seven compounds were isolated. Betulinic acid, quercetin, β -sitosterol, and stigmasterol showed significant ($P < 0.05$) α -amylase and α -glucosidase inhibition. Quercetin, β -sitosterol, and stigmasterol also showed significant ($P < 0.05$) antidiabetic effect in streptozotocin-nicotinamide induced diabetic mice. It is concluded that betulinic acid, quercetin, β -sitosterol, and stigmasterol are responsible for antidiabetic property of *D. indica*. So, the results of present study confirmed that *D.*

TABLE 3: Antidiabetic effect of isolated phytoconstituents in STZ-NIC induced diabetic mice.

Groups/treatment	Blood glucose level (mg/dL)			
	0 h	4 h	8 h	24 h
(I) Vehicle	85.5 ± 3.2	85.94 ± 2.73	86.2 ± 2.4	85.26 ± 1.77
(II) STZ-NIC	237.23 ± 3.83	239.24 ± 4.32	239.83 ± 5.86	241.87 ± 4.44 ^a
(III) STZ-NIC + quercetin	204.34 ± 5.56	173.5 ± 5.25*	162.23 ± 3.57*	165.53 ± 5.57*
(IV) STZ-NIC + β -sitosterol	225.68 ± 3.78	142.34 ± 3.4*	139.5 ± 3.7*	140.27 ± 3.57*
(V) STZ-NIC + stigmaterol	207.93 ± 2.85	158.69 ± 3.84	147.25 ± 4.31*	148.38 ± 3.72*
(VI) STZ-NIC + std.	224.37 ± 4.37	151.37 ± 2.43*	128.47 ± 3.72*	121.25 ± 5.1*

Data represent means ± SEM. * $P < 0.05$ when groups (III) to (VI) are compared with diabetic control, that is, group (II). Std.: standard drug (glibenclamide).

^a $P < 0.05$, when group (II) is compared with group (I).

indica is a potential antidiabetic plant and it should be added in herbal formulations for management of diabetes.

Conflict of Interests

The authors declare that they have no conflict of interests.

Acknowledgment

The authors are thankful to AICTE, New Delhi, for honoring Sunil Kumar with Career Award for Young Teachers and financially supporting the research work (F. no. 1-51/RID/CA/4/2009-10). The authors are also thankful to Professor Mohammed Ali, Jamia Hamdard University, New Delhi, for helping them in spectral elucidation of the phytoconstituents.

References

- [1] S. Wild, G. Roglic, A. Green, R. Sicree, and H. King, "Global prevalence of diabetes: estimates for the year 2000 and projections for 2030," *Diabetes Care*, vol. 27, no. 5, pp. 1047–1053, 2004.
- [2] M. B. Narkhede, "Investigation of in vitro α -amylase and α -glucosidase inhibitory activity of polyherbal extract," *International Journal of Pharmaceutical Research and Development*, vol. 3, no. 8, pp. 97–103, 2011.
- [3] M. I. Kotowaroo, M. F. Mahomoodally, A. Gurib-Fakim, and A. H. Subratty, "Screening of traditional antidiabetic medicinal plants of Mauritius for possible α -amylase inhibitory effects in vitro," *Phytotherapy Research*, vol. 20, no. 3, pp. 228–231, 2006.
- [4] Y.-I. I. Kwon, D. A. Vattam, and K. Shetty, "Evaluation of clonal herbs of Lamiaceae species for management of diabetes and hypertension," *Asia Pacific Journal of Clinical Nutrition*, vol. 15, no. 1, pp. 107–118, 2006.
- [5] H. E. Lebovitz, "Alpha-glucosidase inhibitors," *Endocrinology and Metabolism Clinics of North America*, vol. 26, no. 3, pp. 539–551, 1997.
- [6] O. L. Franco, D. J. Rigden, F. R. Melo, and M. F. Grossi-de-Sá, "Plant α -amylase inhibitors and their interaction with insect α -amylases: structure, function and potential for crop protection," *European Journal of Biochemistry*, vol. 269, no. 2, pp. 397–412, 2002.
- [7] S. Kumar, S. Narwal, V. Kumar, and O. Prakash, " α -glucosidase inhibitors from plants: a natural approach to treat diabetes," *Pharmacology Reviews*, vol. 5, no. 9, pp. 19–29, 2011.
- [8] B. A. Chopade, S. Ghosh, M. Ahire et al., "Antidiabetic activity of *gnidia glauca* and *dioscorea bulbifera*: potent amylase and glucosidase inhibitors," *Evidence-Based Complementary and Alternative Medicine*, vol. 2012, Article ID 929051, 10 pages, 2012.
- [9] K. R. Kritiker and B. D. Basu, *Indian Medicinal Plants*, vol. 1, Oriental Enterprises, Dehradun, India, 2003.
- [10] H. K. Sharma, L. Chhangte, and A. K. Dolui, "Traditional medicinal plants in Mizoram, India," *Fitoterapia*, vol. 72, no. 2, pp. 146–161, 2001.
- [11] M. H. Abdille, R. P. Singh, G. K. Jayaprakasha, and B. S. Jena, "Antioxidant activity of the extracts from *Dillenia indica* fruits," *Food Chemistry*, vol. 90, no. 4, pp. 891–896, 2005.
- [12] D. S. Bhakuni, M. L. Dhar, M. M. Dhar, B. N. Dhawan, and B. N. Mehrotra, "Screening of Indian plants for biological activity. II," *Indian Journal of Experimental Biology*, vol. 7, no. 4, pp. 250–262, 1969.
- [13] S. B. Yeshwante, A. R. Juvekar, D. M. Nagmoti et al., "Anti-inflammatory activity of methanolic extracts of *Dillenia indica* L. leaves," *Journal of Young Pharmacist*, vol. 1, pp. 63–66, 2009.
- [14] A. S. Apu, M. A. Muhit, S. M. Tareq, A. H. Pathan, A. T. M. Jamaluddin, and M. Ahmed, "Antimicrobial activity and brine shrimp lethality bioassay of the leaves extract of *Dillenia indica* linn," *Journal of Young Pharmacists*, vol. 2, no. 1, pp. 50–53, 2010.
- [15] S. K. Sood, R. Bhardwaj, and T. N. Lakhnupal, *Ethnic Indian Plants in Cure of Diabetes*, Scientific Publishers, Jodhpur, India, 2005.
- [16] S. Kumar, V. Kumar, and Om Prakash, "Free Radicals scavenging effect of *Dillenia indica* leaves," *Asian Journal of Pharmaceutical and Biological Research*, vol. 2, pp. 169–173, 2011.
- [17] S. Kumar, V. Kumar, and O. Prakash, "Antidiabetic, hypolipidemic and histopathological analysis of *Dillenia indica* (L.) leaves extract on alloxan induced diabetic rats," *Asian Pacific Journal of Tropical Medicine*, vol. 4, no. 5, pp. 347–352, 2011.
- [18] S. Kumar, V. Kumar, and O. Prakash, "Antidiabetic and anti-hyperlipidemic effects of *Dillenia indica* (L.) leaves extract," *Brazilian Journal of Pharmaceutical Sciences*, vol. 47, no. 2, pp. 373–378, 2011.
- [19] S. Kumar, V. Kumar, and O. Prakash, "Antidiabetic and hypolipidemic activities of *Dillenia indica* extract in diabetic rats," *Journal of Chinese Integrative Medicine*, vol. 9, no. 5, pp. 570–574, 2011.
- [20] C. Hansawasdi, J. Kawabata, and T. Kasai, " α -amylase inhibitors from roselle (*Hibiscus sabdariffa* Linn.) tea," *Bioscience, Biotechnology and Biochemistry*, vol. 64, no. 5, pp. 1041–1043, 2000.

- [21] J.-S. Kim, J. Yang, and M.-J. Kim, "Alpha glucosidase inhibitory effect, anti-microbial activity and UPLC analysis of *Rhus verniciflua* under various extract conditions," *Journal of Medicinal Plant Research*, vol. 5, no. 5, pp. 778–783, 2011.
- [22] R. Barik, S. Jain, D. Qwatra, A. Joshi, G. Tripathi, and R. Goyal, "Antidiabetic activity of aqueous root extract of *Ichnocarpus frutescens* in streptozotocin-nicotinamide induced type-II diabetes in rats," *Indian Journal of Pharmacology*, vol. 40, no. 1, pp. 19–22, 2008.
- [23] A. Kimura, J.-H. Lee, I.-S. Lee et al., "Two potent competitive inhibitors discriminating α -glucosidase family I from family II," *Carbohydrate Research*, vol. 339, no. 6, pp. 1035–1040, 2004.
- [24] A. Junod, A. E. Lambert, W. Stauffacher, and A. E. Renold, "Diabetogenic action of streptozotocin: relationship of dose to metabolic response," *Journal of Clinical Investigation*, vol. 48, no. 11, pp. 2129–2139, 1969.



Hindawi

Submit your manuscripts at
<http://www.hindawi.com>

